Category Archives: AUSTRALIAN HEALTH CARE STOCK

One expensive Healthcare stock – Japara Healthcare Ltd

Japara Healthcare Ltd (ASX: JHC) is aiming to attain a better position in the industry in order to leverage the growing demand at the back of increase in ageing population. The Cumulative Average Growth Rate of government funding during the fiscal 2008 to 2015 period was 8.6% and the government funding has been expected to rise going forward as ACFA estimates

Read more

Cochlear Limited Acquisition of Sycle LLC

Acquisition of Sycle LLC: Cochlear Limited (ASX: COH), the world leader in implantable hearing solutions, acquired 100% of the shares of Sycle LLC (Sycle), the world’s largest provider of audiology practice management software. Sycle software is used by over 7,000 clinics, with over 20,000 hearing professionals in the US, UK and Canada. In the US, the company’s biggest market, Sycle

Read more

Two stocks on a high – Cochlear Limited and Bega Cheese Ltd

Acquisition of Sycle LLC: Cochlear Limited (ASX: COH), the world leader in implantable hearing solutions, acquired 100% of the shares of Sycle LLC (Sycle), the world’s largest provider of audiology practice management software. Sycle software is used by over 7,000 clinics, with over 20,000 hearing professionals in the US, UK and Canada. In the US, the company’s biggest market, Sycle

Read more

For H1FY17, CSL Ltd Robust performance in H1FY17

Robust performance in H1FY17: For H1FY17, CSL Ltd (ASX: CSL) reported for a net profit after tax (NPAT) of $806 million, growth of $87 million or 12% on a reported basis against the prior comparable period (PCP). The underlying NPAT grew 36% and earnings per share (EPS) increased 39% on a constant currency (CC) basis (excluding the one-off items related

Read more

During 9MFY17, Mesoblast Limited Partnering with global pharma players

Partnering with global pharma players: During 9MFY17, Mesoblast Limited (ASX: MSB) executed its planned operational streamlining and reprioritization of projects to successfully absorb the incremental costs of the MPC-150-IM Phase 3 program in advanced chronic heart failure (CHF). Due to these measures, cash outflows for R&D product support costs, manufacturing, and management & administration were reduced for the nine months

Read more

Recently, Bionomics Limited BNC210 data demonstrates it as a novel treatment

BNC210 data demonstrates it as a novel treatment: Recently, Bionomics Limited (ASX: BNO) presented its BNC210 data at the Society of Biological Psychiatry Annual Convention in May 2017 in San Diego, CA. The data highlights a successful Phase 2 double-blinded, placebo controlled clinical trial in Generalized Anxiety Disorder (GAD) patients evaluating the effects of BNC210 on task-related brain activity and

Read more

Three Biotech stocks – Bionomics, Mesoblast & CSL

BNC210 data demonstrates it as a novel treatment: Recently, Bionomics Limited (ASX: BNO) presented its BNC210 data at the Society of Biological Psychiatry Annual Convention in May 2017 in San Diego, CA. The data highlights a successful Phase 2 double-blinded, placebo controlled clinical trial in Generalized Anxiety Disorder (GAD) patients evaluating the effects of BNC210 on task-related brain activity and

Read more
« Older Entries